Ultragenyx Pharmaceutical RARE Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Collaboration And Royalty | $471.14M+9.5% | $481.14M+17.3% | $451.25M+16.3% | $437.15M+19.7% | $430.42M+28.6% | |
| Non Cash Royalty | $112.81M+10.7% | $111.81M+10.7% | $107.83M+13.8% | $105.97M+14.9% | $101.94M+22.5% | |
| Royalty | $303.22M+9.6% | $304.22M+10.6% | $291.81M+13.2% | $289.11M+15.0% | $276.66M+23.3% | |
| Revenue by Geography | ||||||
| Asia Pacific | $18.72M+56.0% | $17.72M+96.8% | $15.99M+159% | $13.15M+240% | $12M+1,360% | |
| EMEA | $115.67M+32.9% | $107.67M+34.6% | $102.93M+47.0% | $97.27M+60.0% | $87.03M+59.4% | |
| Latin America | $157.11M+4.2% | $170.11M+29.9% | $150.18M+15.5% | $144.86M+32.6% | $150.82M+68.7% | |
| North America | $378.21M+11.1% | $377.21M+10.9% | $360.98M+14.1% | $354.36M+15.4% | $340.32M+14.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Ultragenyx Pharmaceutical break its business down?
- Ultragenyx Pharmaceutical (RARE) reports revenue by product across 3 parts — Collaboration And Royalty, Non Cash Royalty and Royalty. Each is extracted from the segment footnotes and tracked over time.
- Where does Ultragenyx Pharmaceutical's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Ultragenyx Pharmaceutical's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.